The Oncotype DX® 21-gene recurrence score and clinical outcomes in hormone receptor-positive, HER2-negative male breast cancer: a scoping review
The prognostic value of RS in MBC appears evident; however, sex-specific thresholds may be necessary to optimize treatment stratification. Given current data limitations, male-inclusive clinical trials are needed to elucidate the predictive value of RS in men and improve personalized treatment strategies.
Authors
- Giulia Pomati (ORCID: https://orcid.org/0000-0001-6715-5443)
- Silvia Mezi (ORCID: https://orcid.org/0000-0003-4746-2678)
- Antonella Chiavassa
- Valentina Silvestri (ORCID: https://orcid.org/0000-0003-0712-9379)
- Laura Ottini (ORCID: https://orcid.org/0000-0001-8030-0449)
Institutions
- IRCCS Istituto Auxologico Italiano (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2025-11-23
- DOI
- https://doi.org/10.1007/s12094-025-04110-w
- Primary Topic
- Male Breast Health Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Associazione Italiana per la Ricerca sul Cancro